CORONARY INTERVENTIONS

In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system

EuroIntervention 2016;12:740-747 published online ahead of print October 2015. DOI: 10.4244/EIJY15M10_01

Juan F. Granada1*, MD; Armando Tellez1,2, MD; William R. Baumbach3, PhD; Brendan Bingham3, MA; Yen-Fang Keng3, PhD; Jeffrey Wessler4, MD; Gerard Conditt1, RCIS; Jennifer McGregor1, BS; Gregg Stone4, MD; Greg L. Kaluza1, MD, PhD; Martin B. Leon4, MD

1. CRF-Skirball Center for Innovation, Orangeburg, New York, NY, USA; 2. Alizee Pathology, Thurmont, MD, USA; 3. Caliber Therapeutics, New Hope, PA, USA; 4. Columbia University Medical College, New York, NY, USA

Aims: Among antirestenotic compounds, sirolimus displays a superior safety profile compared to paclitaxel, but its pharmacokinetic properties make it a challenging therapeutic candidate f

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

drug-eluting balloonextended releasepharmacokineticsporcine coronary artery modelporous angioplasty balloonsirolimus nanoparticle

Coronary interventionsStents and scaffoldsTools, devices and techniques

Share on Facebook Share on Twitter Share on Linkedin

In vivo delivery and long-term tissue retention of nano-encapsulated sirolimus using a novel porous balloon angioplasty system

Latest news